CONMED (NYSE:CNMD) Issues FY 2026 Earnings Guidance

Posted by Brenda Bartman on Oct 30th, 2026

CONMED (NYSE:CNMD – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 4.540-4.610 for the period, compared to the consensus EPS estimate of 4.540. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. Piper Sandler reaffirmed a “neutral” rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a research note on Thursday, July 30th. Zacks Research raised CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. BMO Capital Markets assumed coverage on CONMED in a research note on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective on the stock. Finally, Wells Fargo & Company lifted their price target on shares of CONMED from $46.00 to $49.00 and gave the stock an “equal weight” rating in a report on Thursday. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CONMED currently has an average rating of “Reduce” and an average target price of $44.00.

Check Out Our Latest Stock Report on CNMD

CONMED Stock Down 0.7%

Shares of CONMED stock traded down $0.32 during trading on Friday, hitting $45.40. 80,047 shares of the stock traded hands, compared to its average volume of 504,452. The firm has a market cap of $1.36 billion, a P/E ratio of 18.76, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. CONMED has a 52-week low of $31.44 and a 52-week high of $53.66. The company has a current ratio of 1.48, a quick ratio of 0.69 and a debt-to-equity ratio of 0.63. The stock’s fifty day simple moving average is $47.20 and its 200 day simple moving average is $41.45.

CONMED (NYSE:CNMD – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. CONMED had a return on equity of 14.03% and a net margin of 5.36%. The firm had revenue of $335.56 million during the quarter, compared to analyst estimates of $336.28 million. During the same quarter in the prior year, the business posted $1.08 EPS. The business’s revenue for the quarter was down .7% compared to the same quarter last year. On average, equities analysts predict that CONMED will post 4.54 earnings per share for the current fiscal year.

Key CONMED News

Here are the key news stories impacting CONMED this week:

Positive Sentiment: Q3 earnings beat estimates: CONMED reported adjusted earnings of $1.04 per share, above the $1.00 consensus estimate. The result provides some support for the stock, although it declined from $1.08 a year earlier. Conmed Q3 Earnings Top Estimates
Positive Sentiment: 2026 EPS guidance was raised or maintained at a favorable level: Management forecast full-year EPS of $4.54-$4.61, compared with the $4.54 analyst consensus. The top end of the range is modestly above expectations, potentially improving investor confidence in profitability. Full-year revenue guidance of approximately $1.4 billion was maintained in line with estimates.
Positive Sentiment: Analysts increased their price targets: JPMorgan raised its target from $45 to $50, while Wells Fargo increased its target from $46 to $49. These revisions indicate improved valuation support, although both firms maintained neutral or equal-weight ratings. JPMorgan price target update Wells Fargo price target update
Neutral Sentiment: Revenue was broadly in line: Third-quarter sales of $335.56 million were slightly below the $336.28 million consensus, limiting the positive impact of the EPS beat. CONMED third-quarter financial results
Negative Sentiment: Underlying growth was weak: Quarterly revenue decreased 0.7% year over year, while EPS fell from $1.08 to $1.04. The limited sales growth and lower year-over-year earnings help explain why analysts remain cautious despite the guidance and price-target increases.

CONMED Company Profile

(Get Free Report)

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.